Climbing as an Add-On Treatment Option for Patients with Severe Anxiety Disorders and PTSD: Feasibility Analysis and First Results of a Randomized Controlled Longitudinal Clinical Pilot Trial

被引:5
|
作者
Bichler, Carina S. [1 ]
Niedermeier, Martin [1 ]
Huefner, Katharina [2 ]
Galffy, Matyas [2 ]
Gostner, Johanna M. [3 ]
Nelles, Philipp [2 ]
Schoettl, Stefanie E. [1 ]
Sperner-Unterweger, Barbara [2 ]
Kopp, Martin [1 ]
机构
[1] Univ Innsbruck, Dept Sport Sci, Fuerstenweg 185, A-6020 Innsbruck, Austria
[2] Innsbruck Med Univ, Univ Hosp Psychiat 2, Dept Psychiat Psychotherapy Psychosomat & Med Psy, Anichstr 35, A-6020 Innsbruck, Austria
[3] Med Univ Innsbruck, Inst Med Biochem, Bioctr, Innrain 80-82, A-6020 Innsbruck, Austria
关键词
anxiety disorder; post-traumatic stress disorder; exercise; physical activity; climbing therapy; biomarker; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; PHYSICAL-ACTIVITY; SERUM TRYPTOPHAN; NORDIC WALKING; EXERCISE; PEOPLE; HEALTH; METAANALYSIS;
D O I
10.3390/ijerph191811622
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: Exercise has considerable effects on physical and psychological health. Anxiolytic effects of climbing exercise have been found in people suffering from depression. However, there are no studies on patients with severe anxiety disorders or post-traumatic stress disorder (PTSD) practicing climbing as add-on treatment. Additionally, many studies on physical therapy fail to use adequate active control groups. Therefore, this study aimed to investigate the feasibility of a four-week climbing exercise program for patients with anxiety disorders or PTSD in comparison to a standard exercise treatment and a social control group. Methods: Outpatients diagnosed with anxiety disorders or PTSD (F 40, F 41, F 43.1 according to ICD-10) were randomly assigned to (a) climbing exercise (n = 27), (b) Nordic walking exercise (n = 23), or (c) control condition (n = 23) providing the same amount of social contact for eight sessions of 90 minutes each. Psychological parameters (symptom severity, worry symptoms, self-efficacy, quality of life) and biological parameters were assessed at the beginning and at the end of the four-week program. Additionally, follow-up assessments were conducted three and six months after the program ended. Results: Sixty outpatients (75% female) aged 18-65 years with a longstanding history of a mental disorder (>10 years) and classified as treatment-resistant (95%) and with averaging 3.8 psychiatric comorbidities completed the pilot trial. After participation, symptoms of anxiety disorders were significantly reduced (p = 0.003), and health-related characteristics significantly improved (depression symptoms: p < 0.001, worry symptoms: p < 0.001, self-efficacy: p < 0.001, quality of life-physical health: p = 0.002, quality of life-psychological health: p = 0.006) in all groups. The feasibility of conducting climbing exercises for the patient groups could be demonstrated, and a general acceptance in the groups was recorded. No significant time-by-group interactions were found. At the completion of the program, psychological parameters improved, while biological parameters remained the same in all three groups. Conclusions: Participation in the climbing group as well as in Nordic walking and social contact groups demonstrated beneficial results in patients with anxiety disorders and PTSD with severe mental burden. Nevertheless, climbing did not show any additional clinically relevant benefits compared to Nordic walking or social contact. Studies with larger sample sizes and qualitative insights are needed to further evaluate the possible benefits of climbing in this population.
引用
收藏
页数:18
相关论文
共 49 条
  • [41] Remdesivir is Effective for Moderately Severe Patients: A Re-Analysis of the First Double-Blind, Placebo-Controlled, Randomized Trial on Remdesivir for Treatment of Severe COVID-19 Patients Conducted in Wuhan City
    Shih, Weichung J.
    Shen, Xin
    Zhang, Peng
    Xie, Tai
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2020, 12 : 15 - 21
  • [42] Pulmonary artery denervation in patients with residual pulmonary hypertension after pulmonary endarterectomy: one-year results of the first -in-man, sham-controlled, pilot randomized clinical trial
    Romanov, A.
    Cherniavskiy, A.
    Novikova, N.
    Edemskiy, A.
    Ponomarev, D.
    Shabanov, V.
    Losik, D.
    Kretov, E.
    Stenin, I.
    Elesin, D.
    Pokushalov, E.
    Steinberg, J. S.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2541 - 2541
  • [43] Study protocol for RUFUS-A randomized mixed methods pilot clinical trial investigating the relevance and feasibility of rumination-focused cognitive behavioral therapy in the treatment of patients with emergent psychosis spectrum disorders
    Clemmensen, Lars
    Lund, Christin Nymann
    Andresen, Birgitte S.
    Midtgaard, Julie
    Glenthoj, Louise Birkedal
    PLOS ONE, 2024, 19 (01):
  • [44] History of depressive and/or anxiety disorders as a predictor of treatment response: A post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia
    Pae, Chi-Un
    Masand, Prakash S.
    Marks, David M.
    Krulewicz, Stan
    Peindl, Kathleen
    Mannelli, Paolo
    Patkar, Ashwin A.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (06): : 996 - 1002
  • [45] Effect of Godelieve Denys-Struyf (GDS) muscle and articulation chain treatment on clinical variables of patients with chronic low back pain and lumbar disc degeneration: a pilot feasibility randomized controlled trial
    Sidsel Lombardo
    Gunvor Hilde
    Milada Cvancarova Småstuen
    Margreth Grotle
    Pilot and Feasibility Studies, 9
  • [46] Effect of Godelieve Denys-Struyf (GDS) muscle and articulation chain treatment on clinical variables of patients with chronic low back pain and lumbar disc degeneration: a pilot feasibility randomized controlled trial
    Lombardo, Sidsel
    Hilde, Gunvor
    Smastuen, Milada Cvancarova
    Grotle, Margreth
    PILOT AND FEASIBILITY STUDIES, 2023, 9 (01)
  • [47] A Double-blind. Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients
    Shetty, Adarsh
    Chandrakant, Nirhali Sonali
    Darnule, Rahul Ashok
    Manjunath, B. G.
    Sathe, Prachee
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2022, 26 (08) : 913 - 919
  • [48] The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
    Chaccour, Carlos
    Casellas, Aina
    Blanco-Di Matteo, Andres
    Pineda, Inigo
    Fernandez-Montero, Alejandro
    Ruiz-Castillo, Paula
    Richardson, Mary-Ann
    Rodriguez-Mateos, Mariano
    Jordan-Iborra, Carlota
    Brew, Joe
    Carmona-Torre, Francisco
    Giraldez, Miriam
    Laso, Ester
    Gabaldon-Figueira, Juan C.
    Dobano, Carlota
    Moncunill, Gemma
    Yuste, Jose R.
    Del Pozo, Jose L.
    Rabinovich, N. Regina
    Schoening, Verena
    Hammann, Felix
    Reina, Gabriel
    Sadaba, Belen
    Fernandez-Alonso, Mirian
    ECLINICALMEDICINE, 2021, 32
  • [49] Persistent clinical improvement in genital psoriasis through one year of treatment with ixekizumab: Results of a randomized, placebo-controlled phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)
    Guenther, Lyn
    Bleakman, Alison Potts
    Weisman, Jamie
    Poulin, Yves
    Spelman, Lynda
    Burge, Russel
    Erickson, Janelle
    Todd, Kristin
    Bertram, Clinton C.
    Ryan, Caitriona
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB254 - AB254